Table of Contents
<< Previous Issue | Mar 2011 (Vol: 2011, Issue: 3) | Next Issue >> |
- Section: Licensing
-
Astellas Gains Ex-Asia Rights to Tivozanib from AVEO in Potential US$1.4 B Deal
-
Cell Therapeutics Expands its Late-Stage Oncology Pipeline with Chroma Therapeutics’ Tosedostat
- Section: Mergers & Acquisitions
-
Genzyme Finally Agrees to US$20.1 B Plus CVR Takeover by Sanofi-aventis
-
Gilead Continues its Diversification Strategy with Acquisition of Calistoga Pharmaceuticals
-
Forest Laboratories Agrees to Acquire Clinical Data for US$1.2 B Upfront
-
Kyowa Hakko Kirin Makes Takeover Bid for ProStrakan to Expand in Foreign Markets
-
Daiichi Sankyo Targets US Oncology Market with US$935 M Plexxikon Acquisition
- Section: Research & Development
-
Lycera and Merck & Co. to Develop Autoimmune Disease Drugs Targeting Th17 Cells
-
Epizyme Signs its Second Major Deal of 2011